---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-023838"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:33:49.373738+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics prices $550M public offering of 6.47M shares at $85/share

## Summary
- Gross proceeds ~$550M from 6.47M shares at $85; underwriters have 30-day option for 970,650 additional shares.
- Net proceeds to fund development of VK2809, VK2735, VK0214 programs and general corporate purposes.
- Offering expected to close March 4, 2024; Morgan Stanley & Leerink Partners lead underwriters.
- Directors and executive officers subject to 90-day lock-up until May 28, 2024.

## SEC filing metadata
- accession: 0000950170-24-023838
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024023838/0000950170-24-023838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024023838/vktx-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-023838
- JSON: https://secwatch.observer/filing/0000950170-24-023838.json
- Plain text: https://secwatch.observer/filing/0000950170-24-023838.txt

## Key facts
- Material Agreements
  Viking Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC valued at approximately $550.0 million (effective 2024-02-28).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Morgan Stanley & Co. LLC and Leerink Partners LLC
  - Value: approximately $550.0 million
  - Effective: 2024-02-28
  source text: On February 28, 2024, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 6,471,000 shares of the Company’s common stock (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017024023838/0000950170-24-023838-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.